Earnings call briefThird-quarter 2026
GSK now expects up to GBP 1 billion of charges in 2026
GSK also said it expects 2026 EPS growth in the low half of its guidance range.
GetSignal GSK GSK
GSK said on its third-quarter call that it now expects charges of up to GBP 1 billion in 2026 under its Accelerate Growth program.
The company said it now expects royalties of around GBP 900 million for the year. GSK said it expects full-year interest of GBP 700 million to GBP 750 million, including around GBP 160 million relating to the Nuvalent acquisition.
Quotes from the call
“We are moving at pace and ahead of schedule, and since July, we have initiated a series of changes across the organization to streamline support services, simplify our supply chain, and reallocate resources. We now expect charges of up to GBP 1 billion in 2026.”
“EPS growth is expected to be in the low half of the range, with full year interest expected to be GBP 700 million-GBP 750 million, including around GBP 160 million relating to the acquisition of Nuvalent.”
Key facts from the call
- Expected 2026 charges
- Up to GBP 1 billion
- Expected 2026 royalties
- Around GBP 900 million
- Expected 2026 full-year interest
- GBP 700 million to GBP 750 million
- Expected 2026 EPS growth
- Low half of the range
Source: GSK's third-quarter 2026 earnings call, October 28, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
